Drug details
Cotellic (cobimetinib tablets)
type of Antineoplastics MEK Inhibitors
Cotellic (cobimetinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- nausea,
- upper stomach pain,
- loss of appetite,
- itching,
- dark urine,
- vomiting,
- easy bruising,
- shortness of breath,
- confusion,
- fast heartbeats,
- tiredness,
- clay-colored stools,
- yellowing of the skin or eyes (jaundice),
- chest pain,
- dizziness,
- headache,
- wheezing,
- cough,
- skin pain,
- unexplained muscle pain,
- swelling in your feet or ankles,
- slurred speech,
- vision changes,
- unusual bleeding (nosebleeds, bleeding gums),
- bloody or tarry stools,
- coughing up blood,
- vomit that looks like coffee grounds,
- severe weakness,
- seeing halos around lights,
- loss of coordination,
- feeling unsteady,
- redness,
- tenderness,
- red or pink urine,
- partial vision loss,
- weakness (especially if you also have fever and dark colored urine),
- pimples or bumps,
- thickened or wrinkled skin, and
- skin rash that spreads and causes blistering and peeling
The following drugs are related to Cotellic, either as a replacement or used together:
- Proleukin (aldesleukin for injection)
- Azedra (iobenguane i 131 injection)
- Mektovi (binimetinib tablets)
- Braftovi (encorafenib capsules)
- Intron A (interferon alfa-2b, recombinant for injection)
- Yervoy (ipilimumab injection)
- Keytruda (pembrolizumab for injection)
- Mekinist (trametinib tablets)
- Opdualag (nivolumab and relatlimab-rmbw injection)
- Opdivo (nivolumab injection)
- Zelboraf (vemurafenib)